For the year ending 2025-12-31, IBRX made $113,288K in revenue. -$351,398K in net income. Net profit margin of -310.18%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenue | 113,288 | 14,745 | 622 | 240 |
| Cost of sales | 753 | 0 | - | - |
| Research and development-Nonrelated Party | 207,875 | - | - | - |
| Research and development-Related Party | 10,684 | - | - | - |
| Research and development (including amounts with related parties) | - | 190,144 | 232,366 | 248,149 |
| Selling, general and administrative-Nonrelated Party | 147,180 | - | - | - |
| Selling, general and administrative (including amounts with related parties) | - | 168,783 | 129,620 | 102,708 |
| Selling, general and administrative-Related Party | 2,823 | - | - | - |
| Impairment of intangible assets | 0 | 0 | 886 | 681 |
| Total operating costs and expenses | 369,315 | 358,927 | 362,872 | 351,538 |
| Loss from operations | -256,027 | -344,182 | -362,250 | -351,298 |
| Interest and investment income, net | 6,405 | 7,975 | 1,131 | -3,090 |
| Interest expense (including amounts with related parties) | - | 114,670 | - | - |
| Change in fair value of related-party convertible notes | - | 43,472 | - | - |
| Interest expense-Related Party | 60,886 | - | - | - |
| Interest expense related to revenue interest liability | 51,540 | 39,657 | - | - |
| Change in fair value of warrant liabilities | -49,089 | -19,955 | 47,600 | -13,460 |
| Change in fair value of related-party convertible note-Related Party | -42,773 | - | - | - |
| Change in fair value of derivative liabilities | 6,398 | 13,477 | - | - |
| Interest expense (including amounts with related parties) | - | - | 129,198 | 63,515 |
| Interest expense-Nonrelated Party | 99 | - | - | - |
| Change in fair value of related-party convertible note | - | - | -36,203 | - |
| Loss on equity method investment | 0 | 0 | -7,549 | -12,107 |
| Other expense, net | -2,174 | -15 | -2,223 | -736 |
| Total other expense, net | -95,580 | -69,463 | -221,642 | -65,988 |
| Loss before income taxes and noncontrolling interests | -351,607 | -413,645 | -583,892 | -417,286 |
| Income tax benefit | -135 | 0 | -40 | 34 |
| Net loss | -351,472 | -413,645 | -583,852 | -417,320 |
| Net loss attributable to noncontrolling interests, net of tax | -74 | -81 | -656 | -753 |
| Net loss attributable to immunitybio common stockholders | -351,398 | -413,564 | -583,196 | -416,567 |
| Basic EPS | -0.38 | -0.59 | -1.15 | -1.04 |
| Diluted EPS | -0.38 | -0.62 | -1.15 | -1.04 |
| Basic Average Shares | 919,863,000 | 697,312,000 | 508,635,592 | 399,900,374 |
| Diluted Average Shares | 919,863,000 | 700,443,000 | 508,635,592 | 399,900,374 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)